Navigating the Inflation Reduction Act:

Reassessing Evidence and Value Needs for Price Negotiations

On Thursday, December 5, 2024, V-BID Center director, A. Mark Fendrick, spoke to attendees of an Xtalks webinar that explored the impact of the Inflation Reduction Act‘s Medicare price negotiation provisions on the pharmaceutical industry, focusing on CMS policy guidance and strategies for developing evidence to demonstrate product value.

Dr. Fendrick was part of an expert panel on market access, payer perspectives, and actionable steps for aligning with new regulatory expectations. Find associated resources below.

IRA White Paper
How To Make Sure the IRA
Works For All Patients
CMS Must Obtain Clinician Input
To Prevent Access Barriers
CMS Should Do More To Fulfill The IRA's Promise To Lower Drug Costs
Op Ed: New Minnesota Board Could Make Some Medicines Harder to Get
Unintended Consequences of IRA Drug Price Negotiations